Nigella sativa L as a potential phytotherapy for coronavirus disease 2019.
L as a potential phytotherapy for coronavirus disease 2019: A mini review of in silico studies.
AI Summary
Key Findings
Abstract
Background: Coronaviruses are responsible for several human diseases, such as the infectious novel coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).is a natural food supplement with a known safety profile that may provide a wealth of documented antiviral compounds. Objective: To explore the studies supporting thepotential for hitting SARS-CoV-2 targets. Methods: A literature search for published or preprint in silico studies between 1990 and 2020 in electronic databases (PubMed, Science Direct, Scopus, and Google Scholar) was performed for the terms Nigella sativa,, and. Results: At least 8 in silico studies have shown that some compounds of, including nigelledine,α-hederin, hederagenin, thymohydroquinone, and thymoquinone, had high to moderate affinity with SARS-CoV-2 enzymes and proteins. These compounds may potentially inhibit SARS-CoV-2 replication and. Conclusions: These preliminary data of in silico studies proposeas a potential phytotherapy candidate for COVID-19. Further preclinical experimental evidence is required followed by a Phase I clinical trial. (. 2020; 81:XXX-XXX).
Affiliation
Dr Abdulrahman E Koshak
External References
- PubMed ID:
- 32863400
Comments
Sign in or create a free account to join the conversation.
Sign in to commentBe the first to comment.